Female sex workers (FSW) face a disproportionately high risk of contracting Human Papillomavirus (HPV) due to multiple sexual partners. Consequently, establishing the efficacy of HPV vaccine immunogenicity in this demographic is vital for public health strategies. Recent findings from a pilot study in Vietnam suggest that even individuals with high exposure risks can achieve a robust immune response through vaccination.

Assessing HPV Vaccine Immunogenicity in High-Risk Populations

Scientists recruited 63 FSWs aged 18 to 26 years for this investigation. Notably, the participants followed the standard three-dose schedule of the quadrivalent Gardasil (4vHPV) vaccine. At the start, nearly 29% of the women tested positive for high-risk HPV DNA. However, the results post-vaccination were remarkably encouraging. By month seven, all participants reached 100% seropositivity for both HPV 16 and HPV 18. Furthermore, the vaccine induced significant neutralizing antibody responses against related types like HPV 52 and HPV 58.

The study also highlighted variations in immune responses based on prior exposure. Researchers observed higher antibody titers in participants who were HPV-DNA negative at the baseline. Specifically, those with active infections at the start showed lower but still significant antibody responses. This suggests that while previous exposure might dampen the peak response, the vaccine remains highly immunogenic across the group. Therefore, healthcare providers should prioritize vaccination for high-risk individuals regardless of their previous exposure history.

Clinical Impact of HPV Vaccine Immunogenicity

Does the vaccine still work if a woman has already been exposed to HPV? Clinical data indicates that the vaccine provides protection against types to which the individual has not yet been exposed. Moreover, it may prevent reinfection with previously cleared types. In the Indian context, organizations like the Federation of Obstetric and Gynaecological Societies of India (FOGSI) recommend vaccination for women up to age 45. Consequently, integrating high-risk groups into national immunization drives could significantly reduce the cervical cancer burden.

Frequently Asked Questions

How effective is the HPV vaccine in individuals with multiple sexual partners?

The vaccine is highly effective. Studies show that a complete three-dose series induces 100% seropositivity for high-risk types 16 and 18, even in populations with high exposure risk like female sex workers.

Can a woman receive the HPV vaccine if she already tested positive for HPV DNA?

Yes. While the vaccine is not therapeutic and does not clear existing infections, it protects against other high-risk HPV types included in the vaccine that the individual has not yet contracted.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Van Nguyen T et al. Immunogenicity of HPV Vaccine in a High-Risk and Understudied Group: Female Sex Workers. J Infect Dis. 2026 Mar 01. doi: undefined. PMID: 41764658.


2. World Health Organization (WHO). HPV and Cervical Cancer Fact Sheet. 2024.


3. Federation of Obstetric and Gynaecological Societies of India (FOGSI). Good Clinical Practice Recommendations on Prevention and Management of Cervical Cancer. 2023.